⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19286822 | 0.65 | — | — | |
| SCHEMBL11407122 | 0.65 | — | — | |
| SCHEMBL1937766 | 0.65 | — | — | |
| SCHEMBL23033807 | 0.61 | — | — | |
| SCHEMBL18799918 | 0.60 | — | — | |
| SCHEMBL21698106 | 0.60 | — | — | |
| SCHEMBL23277327 | 0.57 | — | — | |
| SCHEMBL2739417 | 0.53 | — | — | |
| SCHEMBL24828270 | 0.53 | — | — | |
| SCHEMBL16856767 | 0.51 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676591-A2 | SMALL MOLECULE FSH RECEPTOR MODULATORS | Ferring B.V. (NL) | 2026-01-14 | — | — | EP | disclosed |
| EP-4558485-A1 | TEAD INHIBITORS AND METHODS OF USE | Sporos Biodiscovery, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119497708-A | TEAD inhibitors and methods of use | 思博睿生物探索公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024259171-A9 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2024259171-A2 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024184461-A2 | SMALL MOLECULE FSH RECEPTOR MODULATORS | FERRING B.V. (NL) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024020350-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIODISCOVERY, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-3046921-A2 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015095301-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | IRM LLC (BM) | 2015-06-25 | — | — | WO | disclosed |
| US-20150087658-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2015042078-A2 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20150087658-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087658-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2014047662-A2 | INDAZOLE DERIVATIVES AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2008128711-A1 | INSECTICIDAL ARYL PYRROLIDINES | BAYER CROPSCIENCE AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| US-20020115669-A1 | Oxazolidinone chemotherapeutic agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
| WO-2002018354-A1 | OXAZOLIDINONES AND THEIR USE AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |